Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 13/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | BMX | P51813 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454435 | 0.92 | RPS6KB1 (0.49) | MAPK14CSF1RKITBRAFABL1 | |
| SCHEMBL6455326 | 0.90 | PIP4K2A (0.55) | MAPK14CSF1RKITBRAFABL1 | |
| SCHEMBL6454372 | 0.89 | CSF1R (0.55) | MAPK14CSF1RKITBRAFABL1 | |
| SCHEMBL14278692 | 0.89 | PIP4K2A (0.43) | MAPK14BRAFSRCKDR | |
| SCHEMBL6450311 | 0.89 | CSF1R (0.53) | MAPK14CSF1RKITBRAFABL1 | |
| SCHEMBL6450838 | 0.88 | CSF1R (0.52) | CSF1RKITBRAFABL1SRC | |
| SCHEMBL6450182 | 0.88 | BRAF (0.54) | MAPK14CSF1RKITBRAFABL1 | |
| SCHEMBL6454429 | 0.88 | KDM4E (0.55) | MAPK14CSF1RBRAFABL1SRC | |
| SCHEMBL6450176 | 0.87 | CSF1R (0.53) | MAPK14CSF1RKITBRAFABL1 | |
| SCHEMBL6461376 | 0.87 | CSF1R (0.54) | CSF1RKITBRAFABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-21 | — | — | US | claimed |
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | disclosed |
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | LCK, FYN, BMX | MAPK14 143/4885CSF1R 915/4885KIT 1024/4885 |
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | LCK, FYN, BMX | MAPK14 143/4885CSF1R 915/4885KIT 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.